Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ioanna Barla"'
Autor:
Panagiotis Efentakis, Sofia Lamprou, Manousos Makridakis, Ioanna Barla, Panagiota-Efstathia Nikolaou, Andriana Christodoulou, Costantinos Dimitriou, Nikolaos Kostomitsopoulos, Ioannis Ntanasis-Stathopoulos, Irene Theochari, Maria Gavriatopoulou, Harikleia Gakiopoulou, Androniki Tasouli, Antonia Vlahou, Evangelos Gikas, Nikolaos Thomaidis, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou
Publikováno v:
HemaSphere, Vol 6, Iss 11, p e791 (2022)
Carfilzomib is an irreversible proteasome inhibitor indicated for relapsed/refractory multiple myeloma. Carfilzomib toxicity includes renal adverse effects (RAEs) of obscure pathobiology. Therefore, we investigated the mechanisms of nephrotoxicity de
Externí odkaz:
https://doaj.org/article/fc5d420a1abb40f487384cc2e97d1092
Autor:
Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas
Publikováno v:
Molecules, Vol 27, Iss 22, p 7929 (2022)
Background: Carfilzomib (Cfz) is an anti-cancer drug related to cardiorenal adverse events, with cardiovascular and renal complications limiting its clinical use. Despite the important progress concerning the discovery of the underlying causes of Cfz
Externí odkaz:
https://doaj.org/article/01071e46bd05421ba4a7fc6aab37abf6
Autor:
Nikolaos Anousakis-Vlachochristou, Ioanna Barla, Evagelos Gikas, Manolis Mavroidis, Maria Katsa, Anthi Panara, NIKOLAOS THOMAIDIS, Dennis V. Cokkinos, Konstantinos P. Toutouzas
Publikováno v:
Journal of the American College of Cardiology. 81:1941
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32fa20d3f042fc1eb70bc04093f93681
https://doi.org/10.1016/s0735-1097(23)02385-9
https://doi.org/10.1016/s0735-1097(23)02385-9